vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Hilltop Holdings Inc. (HTH). Click either name above to swap in a different company.
Hilltop Holdings Inc. is the larger business by last-quarter revenue ($300.5M vs $281.3M, roughly 1.1× Guardant Health, Inc.). Hilltop Holdings Inc. runs the higher net margin — 13.0% vs -45.7%, a 58.7% gap on every dollar of revenue. Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 0.6%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
GH vs HTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $300.5M |
| Net Profit | $-128.5M | $39.0M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | 13.0% |
| Revenue YoY | 39.4% | — |
| Net Profit YoY | -15.8% | -12.4% |
| EPS (diluted) | $-1.01 | $0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $300.5M | ||
| Q4 25 | $281.3M | $329.9M | ||
| Q3 25 | $265.2M | $330.2M | ||
| Q2 25 | $232.1M | $303.3M | ||
| Q1 25 | $203.5M | $318.5M | ||
| Q4 24 | $201.8M | $301.1M | ||
| Q3 24 | $191.5M | $305.5M | ||
| Q2 24 | $177.2M | $297.0M |
| Q1 26 | — | $39.0M | ||
| Q4 25 | $-128.5M | $41.6M | ||
| Q3 25 | $-92.7M | $45.8M | ||
| Q2 25 | $-99.9M | $36.1M | ||
| Q1 25 | $-95.2M | $42.1M | ||
| Q4 24 | $-111.0M | $35.5M | ||
| Q3 24 | $-107.8M | $29.7M | ||
| Q2 24 | $-102.6M | $20.3M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | -43.0% | 16.1% | ||
| Q3 25 | -37.3% | 18.4% | ||
| Q2 25 | -45.9% | 16.3% | ||
| Q1 25 | -54.6% | 18.1% | ||
| Q4 24 | -62.4% | 14.7% | ||
| Q3 24 | -61.3% | 13.9% | ||
| Q2 24 | -56.8% | 10.0% |
| Q1 26 | — | 13.0% | ||
| Q4 25 | -45.7% | 12.6% | ||
| Q3 25 | -35.0% | 13.9% | ||
| Q2 25 | -43.0% | 11.9% | ||
| Q1 25 | -46.8% | 13.2% | ||
| Q4 24 | -55.0% | 11.8% | ||
| Q3 24 | -56.3% | 9.7% | ||
| Q2 24 | -57.9% | 6.8% |
| Q1 26 | — | $0.64 | ||
| Q4 25 | $-1.01 | $0.68 | ||
| Q3 25 | $-0.74 | $0.74 | ||
| Q2 25 | $-0.80 | $0.57 | ||
| Q1 25 | $-0.77 | $0.65 | ||
| Q4 24 | $-0.90 | $0.55 | ||
| Q3 24 | $-0.88 | $0.46 | ||
| Q2 24 | $-0.84 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | — |
| Total DebtLower is stronger | $1.5B | $990.8M |
| Stockholders' EquityBook value | $-99.3M | $2.2B |
| Total Assets | $2.0B | $15.7B |
| Debt / EquityLower = less leverage | — | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | — | ||
| Q2 25 | $629.1M | — | ||
| Q1 25 | $698.6M | — | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | — | ||
| Q2 24 | $933.7M | — |
| Q1 26 | — | $990.8M | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $-99.3M | $2.2B | ||
| Q3 25 | $-354.5M | $2.2B | ||
| Q2 25 | $-305.5M | $2.2B | ||
| Q1 25 | $-250.8M | $2.2B | ||
| Q4 24 | $-139.6M | $2.2B | ||
| Q3 24 | $-60.1M | $2.2B | ||
| Q2 24 | $-1.6M | $2.1B |
| Q1 26 | — | $15.7B | ||
| Q4 25 | $2.0B | $15.8B | ||
| Q3 25 | $1.3B | $15.6B | ||
| Q2 25 | $1.3B | $15.4B | ||
| Q1 25 | $1.3B | $15.8B | ||
| Q4 24 | $1.5B | $16.3B | ||
| Q3 24 | $1.5B | $15.9B | ||
| Q2 24 | $1.6B | $15.6B |
| Q1 26 | — | 0.46× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $-38.7M | ||
| Q3 25 | $-35.4M | $273.0M | ||
| Q2 25 | $-60.3M | $-234.6M | ||
| Q1 25 | $-62.7M | $5.8M | ||
| Q4 24 | $-64.5M | $273.9M | ||
| Q3 24 | $-51.1M | $515.6M | ||
| Q2 24 | $-94.0M | $-435.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $-55.5M | ||
| Q3 25 | $-45.8M | $271.0M | ||
| Q2 25 | $-65.9M | $-234.6M | ||
| Q1 25 | $-67.1M | $5.0M | ||
| Q4 24 | $-83.4M | $266.8M | ||
| Q3 24 | $-55.3M | $513.8M | ||
| Q2 24 | $-99.1M | $-437.3M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | -16.8% | ||
| Q3 25 | -17.3% | 82.1% | ||
| Q2 25 | -28.4% | -77.4% | ||
| Q1 25 | -33.0% | 1.6% | ||
| Q4 24 | -41.3% | 88.6% | ||
| Q3 24 | -28.9% | 168.2% | ||
| Q2 24 | -55.9% | -147.2% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 5.1% | ||
| Q3 25 | 3.9% | 0.6% | ||
| Q2 25 | 2.4% | 0.0% | ||
| Q1 25 | 2.2% | 0.3% | ||
| Q4 24 | 9.4% | 2.4% | ||
| Q3 24 | 2.2% | 0.6% | ||
| Q2 24 | 2.9% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | -0.93× | ||
| Q3 25 | — | 5.96× | ||
| Q2 25 | — | -6.50× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | — | 7.71× | ||
| Q3 24 | — | 17.36× | ||
| Q2 24 | — | -21.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
